Cite
HARVARD Citation
Sternberg, C. et al. (n.d.). 826PUse of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE. Annals of oncology. p. . [Online].